Novartis’ Exjade Label Expansion To Get Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Indication for non-transfusion dependent thalassemia, a cluster of inherited blood disorders that cause mild anemia, will be reviewed by FDA’s Oncologic Drugs Advisory Committee Nov. 8.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.